logo
Plus   Neg
Share
Email

Clovis Oncology Inc. (CLVS) Is Rising On FDA Breakthrough Designation

Clovis Oncology Inc. (CLVS) announced Tuesday morning that it has been granted Breakthrough Therapy designation from the FDA for Rubraca, a prostate cancer treatment.

Clovis Oncology gapped open sharply higher this morning and is now up 4.62 at $33.76 on above average volume. The stock has climbed to over a 2-week high.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT